Literature DB >> 16082607

Mini-dose pump-prime aprotinin inhibited enhanced fibrinolytic activity and reduced blood loss and transfusion requirements after coronary artery bypass surgery.

Alper Sami Kunt1, Osman Tansel Darcin, Salih Aydin, Deniz Demir, Cuneyt Selli, Mehmet Halit Andac.   

Abstract

OBJECTIVES: Low-dose aprotinin in the pump during cardiopulmonary bypass (CPB) has been shown to improve postoperative hemostasis and platelet preservation. This investigation was undertaken to evaluate the effects of mini-dose pump prime only aprotinin (70 mg) on the hemostatic parameters and blood transfusion requirements in patients undergoing on-pump coronary artery bypass surgery (CABG).
MATERIALS AND METHODS: We studied 86 patients who underwent CABG. Forty patients received mini-dose aprotinin (500.000 KIU [70 mg] in the pump), and a control group of 46 did not. D-dimer level, full blood count, postoperative blood loss, and transfusion requirements were analyzed before, after one hour operation and first day after operation.
RESULTS: Twenty-four-hour postoperative blood loss was significantly reduced in the aprotinin group (188+/- 51.5 ml vs. 818+/- 243.5 ml, [mean +/- standard deviation] p < 0.01). Patients in the aprotinin group also received significantly less banked blood posoperatively than the control group (1.20 +/- 0.52 vs. 3.33 +/- 1.13 Units/per patient (p < 0.04). One hour after operation, and 24 hours after operation D-dimer level was significantly reduced in the aprotinin group (p < 0.008 and p < 0.017, respectively).
CONCLUSIONS: Mini dose pump-prime aprotinin reduces postoperative blood loss, transfusion requirements and yet confers hemostatic improvement through reduced fibrinolysis in patients undergoing routine coronary artery bypass grafting.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082607     DOI: 10.1007/s11239-005-1714-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  8 in total

1.  Effects of minimal-dose aprotinin on coronary artery bypass grafting.

Authors:  N Hayashida; T Isomura; T Sato; H Maruyama; K Kosuga; S Aoyagi
Journal:  J Thorac Cardiovasc Surg       Date:  1997-08       Impact factor: 5.209

Review 2.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

3.  Low-dose and high-dose aprotinin improve hemostasis in coronary operations.

Authors:  R G Speekenbrink; C R Wildevuur; A Sturk; L Eijsman
Journal:  J Thorac Cardiovasc Surg       Date:  1996-08       Impact factor: 5.209

4.  Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens.

Authors:  J H Lemmer; E W Dilling; J R Morton; J B Rich; F Robicsek; D L Bricker; C B Hantler; J G Copeland; J L Ochsner; P O Daily; C W Whitten; G P Noon; R Maddi
Journal:  Ann Thorac Surg       Date:  1996-12       Impact factor: 4.330

Review 5.  Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery.

Authors:  R Davis; R Whittington
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 6.  The efficacy and safety of perioperative antiplatelet therapy.

Authors:  J Christopher Merritt; Deepak L Bhatt
Journal:  J Thromb Thrombolysis       Date:  2004-02       Impact factor: 2.300

7.  Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.

Authors:  E L Alderman; J H Levy; J B Rich; M Nili; B Vidne; H Schaff; G Uretzky; G Pettersson; J J Thiis; C B Hantler; B Chaitman; A Nadel
Journal:  J Thorac Cardiovasc Surg       Date:  1998-11       Impact factor: 5.209

8.  Aprotinin in coronary operation with cardiopulmonary bypass: does "low-dose" aprotinin inhibit the inflammatory response?

Authors:  Lars Englberger; Beat Kipfer; Pascal A Berdat; Urs E Nydegger; Thierry P Carrel
Journal:  Ann Thorac Surg       Date:  2002-06       Impact factor: 4.330

  8 in total
  1 in total

Review 1.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Authors:  David A Henry; Paul A Carless; Annette J Moxey; Dianne O'Connell; Barrie J Stokes; Dean A Fergusson; Katharine Ker
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.